and significant global expertise aligned to our company goals.
Founder / CSO
Head of Quality
Head of Project Management
Björn Englund, Chief Executive Officer
The Board of Directors of Opterion Health AG has appointed Björn Englund as CEO of the Company as of April 2021. Björn started his professional career in 1991 as a sales representative at the Gambro Distributor in Saudi Arabia, gradually took over further responsibilities, and in 1996 he became a Managing Director of Gambro Healthcare Sweden AB. He left Gambro in 2006 and moved to Euromedic where he was Vice President of the Dialysis division until 2011. For the next six years he was the President and CEO of DaVita EMEA, and in 2017 was promoted to COO of DaVita International. He left DaVita in 2018 and has since been an Industrial Advisor for EQT, Stockholm.
Daniel Lustenberger, Chief Financial Officer
Daniel Lustenberger is an experienced international finance, accounting and management consulting professional and joined Opterion Health in September 2021 as Chief Financial Officer (CFO). He is a Swiss Certified Public Accountant, holds an Executive MBA from IMD in Lausanne and has 20 years of life sciences and technology experience.
Daniel supports several start-ups and growth companies, particularly in the life sciences and high tech sectors, as a part-time CFO, business advisor and board member.
Prior to Opterion, he held senior finance positions with Vifor Pharma, Gategroup and DKSH. In his early career, he spent several years with PwC, providing advisory services in M&A, IPOs, process and system improvements, corporate governance and risk management.
Guido Grentzmann, Founder / Chief Scientific Officer
Mylène Fleurant, Head of Quality
Mylène Fleurant joined Opterion Health in July 2021 as Head of Quality having spent more than 20 years in leading quality (QA) functions in the life sciences industry. She worked for 10 years as Region Head Quality Europe at Novartis and implemented global quality systems at Merck Serono. Prior to founding her own consulting company in 2019, Mylène was Global Head of QA at Novimmune and VP Quality Affairs at Alvotech.
Mylène is a chemical engineer and holds a master’s degree from the University of Sherbrooke, Canada, as well as a degree in Quality Assurance Management from L’Ecole de Technologie Supérieure (ETS) at the University of Quebec.
Peter Reinemer, Chief Technology Officer
Peter Reinemer, PhD, joined Opterion Health as Chief Technology Officer (CTO) in July 2021 and has 30 years of experience in the pharmaceutical and biotechnology industries. He started his career at Bayer Pharma, where he worked for over 10 years in discovery research in Germany and Japan.
Peter subsequently served as Chief Scientific Officer, Head of Business Development, Chief Operating Officer and Senior Vice President, Corporate Development, of Proteros, a discovery services company based in Munich and Boston. He co-founded IMD Natural Solutions, developer of the all-natural preservative agent Nagardo®, which was acquired by Lanxess AG in 2017. Peter has an M.Sc. in chemistry from Heinrich Heine University Düsseldorf, a PhD from the Max Planck Institute for Biochemistry/TU Munich, and an MBA.
Ulrike Grimm, Head of Project Management
Opterion Health engaged Ulrike Grimm in June 2020 to establish project excellence for its development program.
Ulrike started her career as a sales representative for Sanol Pharma and joined Merck KGaA in 1997, where she held roles of increasing responsibility starting as team leader for R&D projects and continuing as product leader for Merck’s second commercial oncology drug.
From 2007 to 2010 she was the Vice President of Project and Portfolio Management at Fresenius Biotech. Ulrike joined Vifor Pharma in 2010 and served as the Vice President for Project and Alliance Management as well as Clinical Operations during the next eight years. In 2019 Ulrike started her own consulting company Pro2S AG.